» Articles » PMID: 29614136

The Evolving Landscape of Psoriasis Treatment

Overview
Date 2018 Apr 4
PMID 29614136
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The process of discovering new drugs for plaque psoriasis has revealed much about the multisystemic nature of the disease. Current and emerging biologic agents may reliably achieve a Psoriasis Area and Severity Index (PASI 75) up to 90. Initially, clinicians select therapies based on the severity of the psoriasis. Although mild disease can be treated with topical agents, for patients with moderate to severe disease, concurrent therapy with oral systemic agents, biologics, and/ or phototherapy needs to be considered. In some instances, clinicians may need to combine medications to provide patients with rapid relief of symptoms. Semin Cutan Med Surg 37(supp2):S39-S43.

Citing Articles

Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents.

Drakos A, Torres T, Vender R Pharmaceutics. 2024; 16(1).

PMID: 38258121 PMC: 10819460. DOI: 10.3390/pharmaceutics16010111.


Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.

Lebwohl M, Blauvelt A, Menter A, Papp K, Guenthner S, Pillai R Am J Clin Dermatol. 2019; 20(6):863-871.

PMID: 31493163 PMC: 6872506. DOI: 10.1007/s40257-019-00466-2.


Effectiveness comparisons of traditional Chinese medicine for psoriasis: A Bayesian network meta-analysis.

Wang L, Tao Y, Deng S, Chu L, Li L Medicine (Baltimore). 2019; 98(36):e17055.

PMID: 31490403 PMC: 6739008. DOI: 10.1097/MD.0000000000017055.


Effectiveness comparisons of acupuncture for psoriasis: A Bayesian network meta-analysis protocol.

Xie Z, Zhou Y, Deng S, Ding W, Duan X, Yang L Medicine (Baltimore). 2019; 98(17):e15356.

PMID: 31027118 PMC: 6831452. DOI: 10.1097/MD.0000000000015356.